The risk of HPA axis suppression from glucocorticoid therapy is often exaggerated and can be managed with clinical vigilance.
Vigilance may suffice to avert rare steroid-related adrenal failure; leaves open prospective studies to quantify true suppression risk.
Glucocorticoids undoubtedly affect the HPA axis, but the dangers of steroid-induced suppression have been exaggerated. With vigilance on the part of the physician, the rare case of adrenocortical failure can be prevented.
No takes yet. Share an insight, caveat, or question.
Nicholas P. Christy (1984) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: